NICE Rejects Novartis’ Xolair Use In Younger Children
NICE’s analysis found that omalizumab was only useful in reducing the rate of clinically significant exacerbations in children with asthma who were having three of more exacerbations per year.
NICE’s analysis found that omalizumab was only useful in reducing the rate of clinically significant exacerbations in children with asthma who were having three of more exacerbations per year.